Tian-Lu Cheng Selected Research

Glucuronidase

1/2022	Inhibition of gut microbial β-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesis.
9/2021	A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab.
11/2020	Chemical Constituent of β-Glucuronidase Inhibitors from the Root of Neolitsea acuminatissima.
1/2019	Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo.
11/2017	Specific Inhibition of Bacterial β-Glucuronidase by Pyrazolo[4,3-c]quinoline Derivatives via a pH-Dependent Manner To Suppress Chemotherapy-Induced Intestinal Toxicity.
4/2016	Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation.
1/2015	Impediments to enhancement of CPT-11 anticancer activity by E. coli directed beta-glucuronidase therapy.
1/2015	Discovery of specific inhibitors for intestinal E. coli β-glucuronidase through in silico virtual screening.
12/2014	PET imaging of β-glucuronidase activity by an activity-based 124I-trapping probe for the personalized glucuronide prodrug targeted therapy.
5/2013	In vivo magnetic resonance imaging of mice liver tumors using a new gadolinium-based contrast agent.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tian-Lu Cheng Research Topics

Disease

49	Neoplasms (Cancer) 01/2022 - 05/2004
12	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 07/2004
10	Carcinogenesis 01/2022 - 07/2004
6	Breast Neoplasms (Breast Cancer) 12/2021 - 03/2008
5	Leukemia 01/2021 - 02/2006
4	Diarrhea 09/2021 - 11/2017
4	Colonic Neoplasms (Colon Cancer) 01/2020 - 05/2013
4	Adenocarcinoma 09/2018 - 07/2005
4	Neoplasm Metastasis (Metastasis) 01/2010 - 07/2004
3	Inflammation (Inflammations) 01/2021 - 01/2021
3	Rectal Neoplasms (Rectal Cancer) 01/2020 - 12/2007
3	Infections 01/2019 - 09/2007
2	Anemia 02/2022 - 12/2019
2	Autoimmune Diseases (Autoimmune Disease) 06/2020 - 11/2003
2	Rheumatoid Arthritis 01/2019 - 01/2019
2	Circulating Neoplastic Cells 01/2016 - 04/2007
2	Melanoma (Melanoma, Malignant) 08/2010 - 05/2004
2	Lymphatic Metastasis 02/2008 - 07/2004
2	Adenoma (Adenomas) 12/2006 - 07/2005
1	Dysbiosis 01/2022
1	Nausea 09/2021
1	autosomal dominant familial Periodic fever 01/2021
1	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/2021
1	Experimental Arthritis 01/2021
1	Arthritis (Polyarthritis) 01/2021
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2021
1	Cryopyrin-Associated Periodic Syndromes 01/2021
1	Ovarian Neoplasms (Ovarian Cancer) 01/2021
1	Chronic Disease (Chronic Diseases) 06/2020
1	Communicable Diseases (Infectious Diseases) 06/2020
1	Cardiotoxicity 08/2019
1	Necrosis 01/2019
1	Listeriosis (Listeria Infection) 01/2019
1	Tuberculosis (Tuberculoses) 01/2019
1	Infectious Arthritis (Septic Arthritis) 01/2019
1	Polyps 09/2018
1	Drug-Related Side Effects and Adverse Reactions 11/2017

Drug/Important Bio-Agent (IBA)

15	GlucuronidaseIBA 01/2022 - 09/2009
9	GlucuronidesIBA 11/2017 - 05/2006
8	liposomal doxorubicin (Doxil)FDA Link 12/2021 - 12/2014
8	ProdrugsIBA 04/2016 - 05/2004
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2005
6	monomethoxypolyethylene glycol (MPEG)IBA 12/2021 - 12/2014
6	Irinotecan (Camptosar)FDA LinkGeneric 09/2021 - 01/2015
6	AntigensIBA 01/2021 - 08/2010
6	EnzymesIBA 11/2017 - 05/2006
5	Pharmaceutical PreparationsIBA 01/2021 - 06/2010
5	Biomarkers (Surrogate Marker)IBA 01/2016 - 07/2004
5	Contrast MediaIBA 01/2014 - 02/2009
4	AntibodiesIBA 02/2022 - 05/2013
4	Liposomes (Liposome)IBA 12/2021 - 06/2015
4	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2020 - 01/2016
4	CamptothecinIBA 02/2017 - 07/2012
3	1-dodecylpyridoxal (PLD)IBA 01/2021 - 08/2019
3	Monoclonal AntibodiesIBA 01/2021 - 06/2020
3	CytokinesIBA 01/2021 - 05/2006
3	quinolineIBA 01/2019 - 04/2016
3	Peptides (Polypeptides)IBA 01/2014 - 11/2008
3	Messenger RNA (mRNA)IBA 12/2007 - 09/2005
2	continuous erythropoietin receptor activator FDA Link 02/2022 - 12/2019
2	Immunoglobulin G (IgG)IBA 02/2022 - 06/2015
2	CarcinogensIBA 01/2022 - 01/2015
2	7-ethyl-10-hydroxycamptothecin beta-glucuronideIBA 09/2021 - 01/2015
2	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2019 - 01/2012
2	LigandsIBA 01/2016 - 09/2005
2	Carcinoembryonic AntigenIBA 01/2016 - 04/2007
2	p38 Mitogen-Activated Protein KinasesIBA 04/2015 - 09/2013
2	Interleukin-18 (Interleukin 18)IBA 01/2015 - 06/2010
2	gadolinium 1,4,7,10- tetraazacyclododecane- N,N',N'',N'''- tetraacetateIBA 05/2013 - 11/2012
2	Calcibiotic Root Canal SealerIBA 08/2010 - 07/2004
2	4- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA 05/2006 - 05/2004
1	Immunoglobulin M (IgM)IBA 02/2022
1	Topoisomerase InhibitorsIBA 09/2021
1	SilymarinIBA 09/2021
1	Bevacizumab (Avastin)FDA Link 09/2021
1	Cytotoxins (Cytolysins)IBA 09/2021
1	ofatumumab FDA Link 01/2021
1	canakinumab FDA Link 01/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2021
1	Fibrinogen (Factor I)FDA Link 01/2021
1	Adalimumab (Humira)FDA Link 01/2021
1	InterleukinsIBA 01/2021
1	ferric oxide (iron oxide)IBA 08/2020
1	human ERBB2 proteinIBA 08/2019
1	Anti-Idiotypic AntibodiesIBA 01/2019
1	Infliximab (Remicade)FDA Link 01/2019
1	Diethylhexyl Phthalate (DEHP)IBA 09/2018
1	phthalic acid (phthalate)IBA 09/2018
1	CateninsIBA 09/2018
1	Uridine Diphosphate (UDP)IBA 05/2017
1	Glucuronosyltransferase (UDP Glucuronosyltransferase)IBA 05/2017
1	regorafenibIBA 05/2017

Therapy/Procedure

22	Therapeutics 07/2021 - 07/2005
6	Drug Therapy (Chemotherapy) 11/2020 - 02/2008
2	Immunotherapy 08/2010 - 11/2003
1	Chemoprevention 01/2022
1	Fecal Microbiota Transplantation 01/2020
1	Aftercare (After-Treatment) 01/2018
1	Oral Administration 11/2017